{"nctId":"NCT00369343","briefTitle":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women","startDateStruct":{"date":"2006-09"},"conditions":["Depression","Depressive Disorder","Depressive Disorder, Major"],"count":381,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Peri- and postmenopausal women between the ages of 40 and 70 years, inclusive.\n* A primary diagnosis of MDD, single or recurrent episode, without psychotic features using the modified International Neuropsychiatric Interview (MINI).\n* Montgomery-Asberg Depression Rating Scale (MADRS) total score \\> or = 22 at the screening and baseline visit.\n\nExclusion Criteria:\n\n* Use of oral estrogen-, progestin-, androgen-, or Selective Estrogen Receptor Modulator (SERM)-containing drug products 8 weeks before baseline.\n* Current (within 12 months) psychoactive substance abuse or dependence (including alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.\n* A history or active presence of clinically important medical disease.\n\nAdditional criteria apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.","description":"HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. Change= 8 week adjusted mean HAM-D17 minus baseline adjusted mean HAM-D17","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.64","spread":"0.53"},{"groupId":"OG001","value":"-8.33","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score","description":"CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the patient's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Remission","description":"Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Response to Treatment","description":"A response is defined as ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8","description":"The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= 8 week adjusted mean HAM-A score minus baseline adjusted mean score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.62","spread":"0.44"},{"groupId":"OG001","value":"-5.89","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8","description":"EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.02"},{"groupId":"OG001","value":"0.06","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months","description":"HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50. Change= Final Evaluation mean HAM-D17 minus baseline mean HAM-D17.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.52","spread":"7.17"},{"groupId":"OG001","value":"-12.45","spread":"6.85"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression Improvement (CGI-I) Score","description":"CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale the clinician rates how much the patient's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"1.00"},{"groupId":"OG001","value":"1.56","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Remission","description":"Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"48.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving a Response to Treatment","description":"A responder is defined as a patient with ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression - 17-item (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months","description":"The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= Final Evaluation mean HAM-A score minus baseline mean score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.95","spread":"6.90"},{"groupId":"OG001","value":"-10.38","spread":"5.64"}]}]}]},{"type":"SECONDARY","title":"Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months","description":"EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.26"},{"groupId":"OG001","value":"0.22","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","description":"DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of \"new symptoms\" and \"old (but worse) symptoms\" (1) and 0 for \"old and unchanged symptom,\" \"absent,\" or \"old symptom but improved\" for a total possible range of 0 to 43. A higher score indicates more symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"5.05"},{"groupId":"OG001","value":"2.07","spread":"4.03"},{"groupId":"OG002","value":"1.27","spread":"3.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"2.16"},{"groupId":"OG001","value":"3.32","spread":"4.35"},{"groupId":"OG002","value":"2.47","spread":"3.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"3.13"},{"groupId":"OG001","value":"5.29","spread":"5.96"},{"groupId":"OG002","value":"3.76","spread":"4.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.89"},{"groupId":"OG001","value":"1.41","spread":"2.18"},{"groupId":"OG002","value":"2.46","spread":"3.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Headache","Dry mouth","Nausea","Constipation","Somnolence"]}}}